MAP2K7 and serous adenocarcinoma: Specific genomic patterns provide an opportunity for targeted therapy, such as inhibitors of poly ADP ribose polymerase (PARP) in patients with BRCA1/2 mutations [5], mainly high-grade serous carcinoma, or Ras/Raf/MEK/ERK inhibitors in patients with low-grade serous carcinoma or mucinous ovarian carcinoma [4].